It was first approved in 2017 by the FDA to treat type 2 diabetes in adults and reduce the risk of cardiovascular-related issues, and its also used off-label for weight loss
Warning signs include: Dizziness upon standing Decreased urination or dark urine Dry mouth and increased thirst Muscle weakness or cramping Other Concerning Symptoms Immediate medical attention is warranted if fatigue occurs with: Severe abdominal pain (may indicate pancreatitis) Right upper quadrant pain, fever, or yellowing of skin/eyes (signs of gallbladder disease) Persistent vomiting preventing fluid intake Visual changes or severe headache (especially in patients with diabetes and retinopathy) Chest pain or shortness of breath Signs of allergic reaction (rash, swelling, difficulty breathing) The American Diabetes Association Standards of Care recommend regular monitoring of patients on GLP-1 receptor agonists, including assessment of tolerability, glycemic control, weight changes, and overall well-being
thus, they are important candidates for treating brain diseases
Even my girlfriend has noticed an improvement
ACHIEVE-3 was the head-to-head trial against oral semaglutide in T2D (1,698 patients, 52 weeks), showing orforglipron superiority
